



BIODIEM LTD  
ABN 20 096 845 993  
Level 4,  
100 Albert Rd,  
South Melbourne, Victoria, 3205  
Australia  
Phone: +613 9692 7240  
Web: [www.biodiem.com](http://www.biodiem.com)

## Announcement

### Extension of exercise period for BioDiem options expiring 31 December 2014

Melbourne, 30 December 2014

Options issued by the Company under its Replacement Prospectus dated 1 November 2012 ("Options") are due to expire on 31 December 2014.

The timing of the Options' expiry may mean that Optionholders are unable to make a decision, or to exercise the options, due to the holiday season. Therefore the Board has decided to extend the exercise period, so that the Options will now expire at 5.00pm Melbourne time on Friday 13<sup>th</sup> February 2015.

Shareholders and Optionholders will be notified by mail of this extension. Shareholders and Optionholders are requested to ensure their contact details are up-to-date at the share registry, Computershare ([www.computershare.com.au](http://www.computershare.com.au)).

Optionholders who wish to exercise Options, should complete the option exercise form and deliver it, together with payment for the number of shares in respect of which the options are exercised, to the registered office of the Company. Any option that is not exercised during the extended Exercise Period will automatically lapse. All the other terms of the Options, as described in the Replacement Prospectus remain the same.

**ENDS**

#### About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focussed on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other *vaccine* and *infectious disease treatment* companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Serum Institute of India's Nasovac-S™ is based on BioDiem's technology and is already marketed in India. For additional information, please visit [www.biodiem.com](http://www.biodiem.com).

#### Further information

Julie Phillips, Chief Executive Officer  
BioDiem Ltd  
Phone +61 3 9692 7240  
Email [jphillips@biodiem.com](mailto:jphillips@biodiem.com)  
Twitter @biodiem